Companies
Singlera Genomics
develops multi-cancer early-screening panels including its ColonAiQ product, part of China's growing early-cancer-detection testing base.
- Country
- China
Growth
ColonAiQ / multi-cancer panels
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Total funding reported ranges from approximately $275M to $299M across multiple rounds, with a significant $150M Series B round in 2020 and a strategic investment of over CNY 100 million in June 2024 | enlightenbio.com · insideprecisionmedicine.com |
| Capacity | 20,000-square-meter GMP factory | medica.de |
| Certification | ColonAiQ received NMPA Class III medical device registration certificate (Cert. No. RPS/2432/2024) for colorectal cancer screening in China | medica.de · singlera.com |
| Regulatory approval | ColonAiQ received official approval from the Chinese National Medical Products Administration (NMPA) in May 2024 | singlera.com |
| Production site | Production bases located in Yangzhou and Taizhou, China | medica.de · preqin.com |
| Headcount | Workforce estimates vary, with reports of 300 to 400 professionals and some sources citing lower figures like 31 to 32 employees medium confidence | medica.de |
Independent sources: enlightenbio.com · insideprecisionmedicine.com · medica.de · preqin.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-cancer early detection (MCED) | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.